Skip to main content

Treatment Clinical Trials for Acute Lymphoblastic Leukemia (ALL)

Review the acute lymphoblastic leukemia (all) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 170

Optimized Cord Blood Transplant with Intermediate Intensity Conditioning Regimen for the Treatment of Relapsed High-Risk Hematologic Cancers after First Donor Stem Cell Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Calaspargase Pegol-mknl and Decitabine Combined with Venetoclax for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients with Philadelphia Chromosome-Positive and/ or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Haploidentical Stem Cell Transplant with Umbilical Cord Blood Transplant for the Treatment of Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Mini Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for the Treatment of Relapsed B-Cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Modified Cells (CART19) for the Treatment of Pediatric B cell Acute Lymphoblastic Leukemia
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
2 Step ATG with Preparative Chemotherapy and Methotrexate for the Prevention of Acute GVHD for Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant for Hematopoietic Disorders
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Standard-of-Care Reduced-Intensity Conditioning with Total Body Irradiation for the Treatment of Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
CART22-65s and huCART19 CAR T Cells for the Treatment of Relapsed or Refractory B-ALL
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Genetically Engineered Cells (huCART19) for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland